Date: 
Sunday, August 25, 2013

Dr. Sheila Weiss has been brought on board as DrugLogic’s new Chief Science Officer and Vice President of Research.  Sheila has the responsibility of directing DrugLogic’s Research and Consulting Services.

Prior to joining DrugLogic Sheila Weiss had worked at Optum Lifesciences (a division of UnitedHealth) as Chief Scientist/Principal Epidemiologist and at the University of Maryland Baltimore, as Professor and Founding Director of the Center for Drug Safety.  She has delivered more than 100 seminars and presentations, published numerous articles, and taught health professional and graduate courses in Pharmacoepidemiology, Pharmacovigilance, and Epidemiology. Sheila is a Fellow of the International Society of Pharmacoepidemiology and Visiting Professor at the Johns Hopkins Bloomberg School of Public Health.

One of the early adopters of data mining and “Big Data” analytics, Dr. Weiss has worked with data scientists at NASA, the Center for Hybrid Multicore Productivity Research, and DrugLogic to apply novel mapping and mining techniques to large and complex databases to answer public health and medical questions.

Under Dr Weiss’ direction, DrugLogic’s Research and Consulting Division consults to governments and government agencies, pharmaceutical companies, CRO’s, law firms, healthcare providers and insurers, and investment companies on the safety of drugs and other regulated products (e.g. signal detection and processing, risk management, utilization), registries and surveillance, and predictive analytics.